You are here

  • Home
  • Archive
  • Volume 12, Issue 8
  • Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study

Authors

  • Lambert Assoumou Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France PubMed articlesGoogle scholar articles
  • Raghiatou Baldé Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France PubMed articlesGoogle scholar articles
  • Christine Katlama Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, service des maladies infectieuses, Paris, France PubMed articlesGoogle scholar articles
  • Baptiste Abbar Sorbonne University, Department of Medical Oncology Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France PubMed articlesGoogle scholar articles
  • Pierre Delobel CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, INSERM, UMR1291, Université Toulouse III-Paul Sabatier, Toulouse, France PubMed articlesGoogle scholar articles
  • Thierry Allegre Department of Hematology Oncology & Internal Médicine Centre Hospitalier d’Aix en Provence, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France PubMed articlesGoogle scholar articles
  • Armelle Lavole GRC#04 Theranoscan, Département de Pneumologie et Oncologie Thoracique, AP-HP, Hôpital Tenon, Sorbonne Université, Paris, France PubMed articlesGoogle scholar articles
  • Alain Makinson INSERM U1175, Département de Maladies Infectieuses, Centre Hospitalier Universitaire de Montpellier, Université de Montpellier, Montpellier, France PubMed articlesGoogle scholar articles
  • Olivia Zaegel-Faucher Aix-Marseille Université, APHM Sainte-Marguerite, Service d'immuno-hématologie Clinique, Marseille, France PubMed articlesGoogle scholar articles
  • Laurent Greillier Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique—Hôpitaux de Marseille, Aix-Marseille University, Marseille, France PubMed articlesGoogle scholar articles
  • Cathia Soulie Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, laboratoire de virologie, Paris, France PubMed articlesGoogle scholar articles
  • Marianne Veyri Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département d’Oncologie Médicale, Paris, France PubMed articlesGoogle scholar articles
  • Mathilde Bertheau Inserm-ANRS MIE, clinical research department, Paris, France PubMed articlesGoogle scholar articles
  • Michèle Algarte Genin Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France PubMed articlesGoogle scholar articles
  • Séverine Gibowski Inserm-ANRS MIE, safety department, Paris, France PubMed articlesGoogle scholar articles
  • Anne-Geneviève Marcelin Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, laboratoire de virologie, Paris, France PubMed articlesGoogle scholar articles
  • Kevin Bihan Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Regional Pharmacovigilance Centre, Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France PubMed articlesGoogle scholar articles
  • Marine Baron Sorbonne University, Department of Medical Oncology Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France PubMed articlesGoogle scholar articles
  • Dominique Costagliola Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France PubMed articlesGoogle scholar articles
  • Olivier Lambotte Département d’Immunologie Clinique, AP-HP, Hôpital Bicêtre, Université Paris-Saclay, Le Kremlin Bicêtre, France PubMed articlesGoogle scholar articles
  • Jean-Philippe Spano Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié-Salpêtrière, Département d’Oncologie Médicale, Paris, France PubMed articlesGoogle scholar articles

Citation

Assoumou L, Baldé R, Katlama C, et al
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study
Journal for ImmunoTherapy of Cancer 2024;12:e009728. doi: 10.1136/jitc-2024-009728
Online issue publication 
August 22, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.